share_log

Parkside Financial Bank & Trust Cuts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Parkside Financial Bank & Trust Cuts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Parkside Financial Bank&Trust削減IQVIA控股公司(紐約證券交易所代碼:IQV)的股票頭寸
Defense World ·  2022/09/24 07:32

Parkside Financial Bank & Trust lowered its stake in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 24.0% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 295 shares of the medical research company's stock after selling 93 shares during the period. Parkside Financial Bank & Trust's holdings in IQVIA were worth $64,000 as of its most recent filing with the Securities & Exchange Commission.

Parkside Financial Bank&Trust最近提交給美國證券交易委員會(Securities&Exchange Commission)的文件顯示,該公司在第二季度將其在IQVIA Holdings Inc.(NYSE:IQV-GET Rating)的持股比例降低了24.0%。該基金在此期間出售了93股後,持有295股這家醫學研究公司的股票。截至最近提交給美國證券交易委員會(Securities&Exchange Commission)的文件,Parkside Financial Bank&Trust持有的IQVIA價值6.4萬美元。

Several other institutional investors have also added to or reduced their stakes in IQV. Regatta Capital Group LLC boosted its stake in shares of IQVIA by 2.5% in the 1st quarter. Regatta Capital Group LLC now owns 2,024 shares of the medical research company's stock worth $468,000 after buying an additional 50 shares during the last quarter. Private Capital Group LLC raised its holdings in IQVIA by 8.9% during the first quarter. Private Capital Group LLC now owns 659 shares of the medical research company's stock valued at $152,000 after acquiring an additional 54 shares during the period. Waldron Private Wealth LLC raised its holdings in IQVIA by 4.4% during the first quarter. Waldron Private Wealth LLC now owns 1,389 shares of the medical research company's stock valued at $321,000 after acquiring an additional 59 shares during the period. Vestmark Advisory Solutions Inc. raised its holdings in IQVIA by 6.7% during the first quarter. Vestmark Advisory Solutions Inc. now owns 952 shares of the medical research company's stock valued at $220,000 after acquiring an additional 60 shares during the period. Finally, Peterson Wealth Services grew its position in shares of IQVIA by 5.7% during the second quarter. Peterson Wealth Services now owns 1,105 shares of the medical research company's stock valued at $240,000 after purchasing an additional 60 shares in the last quarter. 86.77% of the stock is currently owned by hedge funds and other institutional investors.

其他幾家機構投資者也增持或減持了IQV的股份。Regatta Capital Group LLC在第一季度將其在IQVIA股票中的持股增加了2.5%。Regatta Capital Group LLC現在擁有這家醫學研究公司2,024股股票,價值46.8萬美元,上個季度又購買了50股。私人資本集團LLC在第一季度將其在IQVIA的持股增加了8.9%。私人資本集團LLC現在擁有這家醫療研究公司659股股票,價值15.2萬美元,在此期間又購買了54股。Waldron Private Wealth LLC在第一季度將其在IQVIA的持股增加了4.4%。Waldron Private Wealth LLC現在擁有這家醫療研究公司1,389股股票,價值321,000美元,在此期間又購買了59股。Vestmark Consulting Solutions Inc.在第一季度將其在IQVIA的持股增加了6.7%。維斯特馬克諮詢解決方案公司(Vestmark Consulting Solutions Inc.)在此期間增持了60股,現在擁有952股這家醫療研究公司的股票,價值22萬美元。最後,彼得森財富服務公司在第二季度將其在IQVIA的股票頭寸增加了5.7%。彼得森財富服務公司(Peterson Wealth Services)現在持有這家醫療研究公司1,105股股票,價值24萬美元,上個季度又購買了60股。86.77%的股票目前由對衝基金和其他機構投資者持有。

Get
到達
IQVIA
IQVIA
alerts:
警報:

Wall Street Analysts Forecast Growth

華爾街分析師預測經濟增長

Several research analysts recently commented on the company. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday. SVB Leerink started coverage on shares of IQVIA in a research note on Friday, July 15th. They issued an "outperform" rating and a $256.00 price objective for the company. Robert W. Baird boosted their price objective on shares of IQVIA from $260.00 to $265.00 in a research note on Friday, July 22nd. Evercore ISI upped their price target on IQVIA from $265.00 to $275.00 in a research report on Friday, July 22nd. Finally, Morgan Stanley upped their price target on IQVIA from $255.00 to $260.00 and gave the stock an "overweight" rating in a research report on Friday, July 22nd. Two investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $275.00.

幾位研究分析師最近對該公司發表了評論。StockNews.com週三在一份研究報告中將IQVIA的評級從“買入”下調至“持有”。SVB Leerink在7月15日星期五的一份研究報告中開始報道IQVIA的股票。他們給出了“跑贏大盤”的評級,併為該公司設定了256.00美元的目標價。羅伯特·W·貝爾德在7月22日星期五的一份研究報告中將IQVIA的股票目標價從260.00美元上調至265.00美元。在7月22日星期五的一份研究報告中,Evercore ISI將IQVIA的目標價從265.00美元上調至275.00美元。最終,摩根士丹利在7月22日週五的一份研究報告中將其在IQVIA的目標價從255.00美元上調至260.00美元,並給予該股“增持”評級。兩名投資分析師對該股的評級為持有,15名分析師對該股的評級為買入。根據MarketBeat的數據,該股的普遍評級為“適度買入”,平均目標價為275.00美元。

IQVIA Stock Down 0.6 %

IQVIA股價下跌0.6%

IQV opened at $189.43 on Friday. The company has a market cap of $35.33 billion, a PE ratio of 31.62, a price-to-earnings-growth ratio of 1.74 and a beta of 1.34. The company has a quick ratio of 0.96, a current ratio of 0.96 and a debt-to-equity ratio of 2.36. IQVIA Holdings Inc. has a twelve month low of $186.24 and a twelve month high of $285.61. The company has a 50-day moving average price of $223.04 and a 200 day moving average price of $219.92.
IQV上週五開盤報189.43美元。該公司市值353.3億美元,市盈率31.62倍,市盈率1.74倍,貝塔係數1.34。該公司的速動比率為0.96,流動比率為0.96,債務權益比率為2.36。IQVIA Holdings Inc.的股價跌至186.24美元的12個月低點和285.61美元的12個月高點。該公司的50日移動均線價格為223.04美元,200日移動均線價格為219.92美元。

IQVIA (NYSE:IQV – Get Rating) last released its quarterly earnings data on Thursday, July 21st. The medical research company reported $2.44 EPS for the quarter, beating analysts' consensus estimates of $2.22 by $0.22. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.49 billion. IQVIA had a net margin of 8.21% and a return on equity of 30.21%. IQVIA's quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.94 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 9.4 earnings per share for the current fiscal year.

IQVIA(NYSE:IQV-GET Rating)上一次發佈季度收益數據是在7月21日星期四。這家醫療研究公司公佈本季度每股收益為2.44美元,比分析師普遍預期的2.22美元高出0.22美元。該公司本季度營收為35.4億美元,而市場普遍預期為34.9億美元。IQVIA的淨利潤率為8.21%,股本回報率為30.21%。IQVIA的季度收入同比增長了3.0%。去年同期,該公司每股收益為1.94美元。賣方分析師預計,IQVIA Holdings Inc.本財年每股收益將達到9.4美元。

About IQVIA

關於IQVIA

(Get Rating)

(獲取評級)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

IQVIA控股公司為美洲、歐洲、非洲和亞太地區的生命科學行業提供先進的分析、技術解決方案和臨牀研究服務。它通過三個部門運作:技術和分析解決方案、研發解決方案和合同銷售和醫療解決方案。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on IQVIA (IQV)
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • Will Crowdstrike Get A Boost From Increased EPS Guidance?
  • Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
  • 2 Semiconductor Stocks To Watch For Reversals
  • 免費獲取StockNews.com關於IQVIA(IQV)的研究報告
  • MarketBeat:回顧一週9/19-9/23
  • 為什麼特斯拉的股票保持彈性?
  • CrowdStrike是否會從增加每股收益指引中獲得提振?
  • 小盤股的裁員是樓市的晴雨表嗎?
  • 需要關注的2只半導體類股走勢逆轉

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Get Rating).

想看看還有哪些對衝基金持有IQV嗎?訪問HoldingsChannel.com獲取IQVIA Holdings Inc.(紐約證券交易所代碼:IQV-GET Rating)的最新13F文件和內幕交易信息。

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.

接受IQVIA日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對IQVIA和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論